Search Clinical Trials
Sponsor Condition of Interest |
---|
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Marker Therapeutics, Inc.
Non-Hodgkin Lymphoma, Adult
Non-Hodgkin Lymphoma, Refractory
Non-Hodgkin Lymphoma, Relapsed
Non Hodgkin Lymphoma
Hodgkin Lymphoma
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion
evaluating safety and efficacy of MT-601 administration to patients with Relapsed or
Refractory Lymphoma. The starting dose administered is 200 x 10^6 cells (flat dosing). expand
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10^6 cells (flat dosing). Type: Interventional Start Date: Jan 2023 |
Hyperpolarized 129Xe MRI Lung Health Cohort
University of Kansas Medical Center
Healthy
A subset of young adults participating in the American Lung Association (ALA) Lung Health
Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and
function. Images will be used to improve the understanding of lung health and early lung
abnormalities that may lead to... expand
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease. Type: Observational Start Date: Nov 2023 |
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI)...
MeMed Diagnostics Ltd.
Lower Respiratory Tract Infection
This is a Prospective, multi-center study enrolling adults subjects presented to the
ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI).
The reason of this study is to demonstrate the MeMed BV can help clinicians make
decisions about using antibiotics in patients with... expand
This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI). The reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care. Type: Interventional Start Date: Jan 2023 |
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine,...
Kura Oncology, Inc.
Acute Myeloid Leukemia
Mixed Lineage Acute Leukemia
Mixed Lineage Leukemia Gene Mutation
Mixed Phenotype Acute Leukemia
Refractory AML
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic
activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and
7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. expand
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. Type: Interventional Start Date: Jul 2023 |
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Advanced Microsatellite Stable Colorectal Carcinoma
Hematopoietic and Lymphatic System Neoplasm
Metastatic Malignant Solid Neoplasm
Metastatic Microsatellite Stable Colorectal Carcinoma
This phase I/II trial studies the side effects and best dose of temozolomide and M1774
and how well they works in treating patients with cancer that has spread from where it
first started (primary site) to other places in the body (metastatic) and may have spread
to nearby tissue, lymph nodes, or... expand
This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. M1774 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Adding M1774 to temozolomide may shrink or stabilize cancer for longer than temozolomide alone. Type: Interventional Start Date: Sep 2023 |
Study of M5049 in DM and PM Participants (NEPTUNIA)
EMD Serono Research & Development Institute, Inc.
Dermatomyositis
Polymyositis
The purpose of this study is to evaluate the efficacy and safety of orally administered
M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and
polymyositis (PM) participants for 24 weeks. expand
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks. Type: Interventional Start Date: Jan 2023 |
iAmHealthy Parents First: A Televideo Parent and Child Obesity Program for Rural Families
University of Kansas Medical Center
Weight Loss
Pediatric Obesity
The purpose of this study is to assess whether providing a parent-only group program
before providing a parent and child group program works better than the parent and child
group program alone. expand
The purpose of this study is to assess whether providing a parent-only group program before providing a parent and child group program works better than the parent and child group program alone. Type: Interventional Start Date: May 2023 |
The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers
Nikki Nollen, PhD, MA
Smoking Reduction
This study will compare the efficacy of menthol-flavored versus tobacco-flavored 4th
generation nicotine salt-based pod-system e-cigarettes in facilitating a switch from
combustible cigarettes to e-cigarettes in adult menthol smokers. expand
This study will compare the efficacy of menthol-flavored versus tobacco-flavored 4th generation nicotine salt-based pod-system e-cigarettes in facilitating a switch from combustible cigarettes to e-cigarettes in adult menthol smokers. Type: Interventional Start Date: Nov 2022 |
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer
Advanced Non-Small Cell Squamous Lung Cancer
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Lung Cancer
NSCLC
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study
designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous
system (CNS) activity, and antitumor activity of BDTX-1535. The study population
comprises adults with either advanced/metastatic... expand
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling. Type: Interventional Start Date: Mar 2022 |
MRI for Screening and Monitoring Scleroderma ILD
University of Kansas Medical Center
Scleroderma
The purpose of this study is to test MRI methods for evaluating patients with
Scleroderma-associated interstitial lung disease. expand
The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease. Type: Observational Start Date: May 2022 |
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
State University of New York - Upstate Medical University
Stroke
Sleep Wake Disorders
Rehabilitation
Recovery of Function
Sleep is critical for health and quality of life; however, little is known about the
prevalence or impact of non obstructive sleep apnea (non-OSA) sleep disorders in people
with stroke. The proposed study aims to characterize the proportion of people with stroke
that have non-OSA sleep disorders and... expand
Sleep is critical for health and quality of life; however, little is known about the prevalence or impact of non obstructive sleep apnea (non-OSA) sleep disorders in people with stroke. The proposed study aims to characterize the proportion of people with stroke that have non-OSA sleep disorders and their impact on recovery of activities of daily living, functional mobility, and participation along the continuum of recovery in people with stroke. Type: Observational Start Date: Mar 2021 |
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
University of Kansas
Delay Discounting
Many health-relevant decisions involve intertemporal (now vs. later) tradeoffs. Extensive
literature indicates that many negative health and financial consequences suffered in
mid-life are linked to adversity and disadvantage during early developmental periods of
life. Individuals who continue to... expand
Many health-relevant decisions involve intertemporal (now vs. later) tradeoffs. Extensive literature indicates that many negative health and financial consequences suffered in mid-life are linked to adversity and disadvantage during early developmental periods of life. Individuals who continue to engage in these types of unhealthy behaviors despite awareness of the health consequences are exhibiting an inability to delay gratification. Delay discounting (DD) is quantified in human studies by determining the rate at which an individual discounts a delayed reward, while executive function (EF) is defined as the set of cognitive processes that are responsible for helping individuals manage life tasks and achieve goals. This research will attempt to reduce DD via EF training in a population of mid-life individuals with risk factors established during early-life disadvantage. Type: Interventional Start Date: Nov 2014 |
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Daiichi Sankyo
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized
by autoantibody production, inflammation, and tissue damage in multiple organs. Standard
of care therapies used to treat SLE are only partially effective and have a wide range of
toxicities. There is a need for... expand
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE. Type: Interventional Start Date: Jun 2023 |
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc.
Autosomal Dominant Polycystic Kidney Disease
ADPKD
Polycystic Kidney, Autosomal Dominant
Primary Objectives
- To assess the safety and tolerability of RGLS8429
- To assess the impact of RGLS8429 on ADPKD biomarkers
Secondary Objectives
- To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)
- To characterize the pharmacokinetic (PK) properties... expand
Primary Objectives - To assess the safety and tolerability of RGLS8429 - To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives - To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) - To characterize the pharmacokinetic (PK) properties of RGLS8429 - To assess the impact of RGLS8429 on renal function Type: Interventional Start Date: Oct 2022 |
MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
Microvention-Terumo, Inc.
Intracranial Aneurysm
The objective of this study is to generate contemporaneous clinical data to facilitate a
reasonable comparison of the performance of the FRED™ X™ device with the performance of
the FRED™ device. The data generated from this study will be compared to the safety and
effectiveness of the FRED™ device... expand
The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study. Type: Interventional Start Date: Sep 2022 |
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate
the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis. expand
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis. Type: Interventional Start Date: Jul 2022 |
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
Breast Cancer
Ovarian Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in
adult subjects with advanced or metastatic epithelial derived solid tumors, including but
not limited to the tumor types listed below. expand
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below. Type: Interventional Start Date: Feb 2022 |
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
Duke University
Metastatic Renal Cell Carcinoma
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer
management and health-related quality of life in patients with mRCC in routine real-world
clinical practice in the United States, including both community and academic treatment
settings. expand
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings. Type: Observational Start Date: Apr 2022 |
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B Cell Lymphoma
High Grade B-cell Lymphoma (HGBCL)
Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Lymphoma
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy,
safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients
with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at
least two lines of therapy. expand
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Type: Interventional Start Date: May 2021 |
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Advanced Cancer
Gastric Cancer
Gastroesophageal-junction Cancer
Pancreatic Cancer
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant
humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in
combination with nivolumab or standard of care. It is being tested against advanced
and/or metastatic solid tumors including gastric,... expand
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers. Type: Interventional Start Date: May 2020 |
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small...
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma
Lung Non-Small Cell Squamous Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy
for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has
been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
may help the body's immune system... expand
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer. Type: Interventional Start Date: Jun 2020 |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or...
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the
genes in a patient's tumor cells may help doctors select the best treatment for patients
that have certain genetic changes. expand
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. Type: Interventional Start Date: Sep 2014 |
Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study...
International Spine Study Group Foundation
Cervical Deformity
Multi-center, prospective, non-randomized study to evaluate outcomes of surgically
treated patients with adult cervical spinal deformity. expand
Multi-center, prospective, non-randomized study to evaluate outcomes of surgically treated patients with adult cervical spinal deformity. Type: Observational Start Date: Aug 2019 |
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness...
LivaNova
Treatment Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is
superior to a no stimulation control in producing a reduction in baseline depressive
symptom severity, based on multiple depression scale assessment tools at 12 months from
randomization. expand
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization. Type: Interventional Start Date: Sep 2019 |
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment...
University of Kansas Medical Center
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Unresectable Melanoma
This phase II trial tests how well lifileucel, with reduce dose fludarabine and
cyclophosphamide for lymphodepletion and interleukin-2, work for treating patients with
melanoma that cannot be removed by surgery (unresectable) or that has spread from where
it first started (primary site) to other places... expand
This phase II trial tests how well lifileucel, with reduce dose fludarabine and cyclophosphamide for lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic).Lifileucel is made up of specialized immune cells called lymphocytes or T cells that are taken from a patient's tumor, grown in a manufacturing facility and infused back into the preconditioned patient to attack the tumor. Giving Lifileucel with a reduced dose of fludarabine and cyclophosphamide for lymphodepletion and interleukin -2 is being studied in patients with unresectable or metastatic melanoma. Type: Interventional Start Date: Dec 2023 |
- Previous
- Next